Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia


This is a phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation.


The purpose of this study is to compare the efficacy of crenolanib with midostaurin administered following induction chemotherapy and consolidation therapy on event-free survival (EFS) in newly diagnosed acute myeloid leukemia subjects with FLT3 mutation.


You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Myeloid Leukemia
  • Age: Between 18 Years - 60 Years
  • Gender: Male or Female

Inclusion Criteria
Confirmed diagnosis of de novo AML
Adequate hepatic function within 48 hours prior to induction chemotherapy
Adequate renal functions within 48 hours prior to induction chemotherapy
Exclusion Criteria
Acute promyelocytic leukemia (APL)
Known clinically active central nervous system (CNS) leukemia
Severe liver disease - Active infections
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known infection with human immunodeficiency virus (HIV)
Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)

Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022 . Study ID: TX9327

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center